Art. 17 Directive (EU) 2001/83

In forcesince 20 Jan 2011cited 8×
1.

Member States shall take all appropriate measures to ensure that the procedure for granting a marketing authorisation for medicinal products is completed within a maximum of 210 days after the submission of a valid application.

Applications for marketing authorisations in two or more Member States in respect of the same medicinal product shall be submitted in accordance with Articles 28 to 39.

2.

Where a Member State notes that another marketing authorisation application for the same medicinal product is being examined in another Member State, the Member State concerned shall decline to assess the application and shall advise the applicant that Articles 28 to 39 apply.

  • Directive (EU) 2004/27Lawamends

  • Directive (EU) 2010/84Lawamends

  • Judgment of the General Court (Ninth Chamber) of 8 September 2016. H. Lundbeck A/S and Lundbeck Ltd v European Commission.Decision

    It is true that that period of 210 days laid down by Article 17(1) of Directive 2001/83 is suspended if the competent authority considers that an application is not valid and asks the undertaking concerned to provide it with further …

    8 Sep 2016 · 62013TJ0472

  • Arrêt du Tribunal (neuvième chambre) du 8 septembre 2016. Sun Pharmaceuticals Industries Ltd, anciennement Ranbaxy Laboratories Ltd et RanbaDecision

    In any event, in the first place, it must be noted that, according to Article 17(1) of Directive 2001/83, the Member States are to take all appropriate measures to ensure that the procedure for granting an MA for medicinal products is …

    8 Sep 2016 · 62013TJ0460

  • Directive (EU) 2022/642Law

    От членове 17 и 18 от Директива 2001/83/ЕО, разглеждани във връзка с протокола, следва, че заявителите за разрешения за търговия, които …

  • Opinion of Advocate General Sharpston delivered on 30 May 2013. Laboratoires Lyocentre v Lääkealan turvallisuus- ja kehittämiskeskus and SosDecision

    If the product is in fact a medicinal product, in principle it cannot be put on the market ‘unless a marketing authorisation has been issued by the competent authorities’. [Article 6(1) of the Medicinal Products Directive. There is …

    30 May 2013 · 62012CC0109

  • Opinion of Mr Advocate General Ruiz-Jarabo Colomer delivered on 7 September 2004. Novartis AG, University College London and Institute of MiDecision

    … státě [Jak to vyplývá z článků 3,4 a 5 směrnice 65/65, z článků 9, 10, 11 a 12 směrnice 75/319 a z článků 17 až 39 směrnice 2001/83 ve znění směrnice 2004/27.]. Ve stanovisku, které jsem přednesl ve výše uvedené …

    7 Sep 2004 · 62003CC0207

  • Judgment of the Court (Seventh Chamber) of 7 December 2017. Merck Sharp & Dohme Corporation v Comptroller-General of Patents, Designs and TrDecision

    On 10 September 2014, that is 209 days after the valid marketing authorisation applications had been submitted and, therefore, within the period laid down in Article 17 of Directive 2001/83, the Bundesinstitut für Arzneimittel und …

    7 Dec 2017 · 62016CJ0567